Resolve nabs $5.8M round to study new lupus drug; Sanofi lotion wipes out lice; PCSK9 combo tackles hypercholesterolemia;

 @FierceBiotech: Trending on FierceBiotech.com : The 2012 Biotech Graveyard. Special Report | Follow @FierceBiotech

 @JohnCFierce: Medivir would like everyone to know that JNJ's hep C drug came from them. Alios outlicensed Vertex drug, but they've always been low profile. | Follow @JohnCFierce

 @RyanMFierce: Sanofi deal bolsters Medidata in record quarter for revenue, boosts number of cloud customers in pharma. More | Follow @RyanMFierce

> James Posada's Resolve Therapeutics in Seattle has raised $5.8 million, providing enough cash to start clinical studies of an experimental lupus drug in 2013. Resolve describes RSLV-132 as a "new approach to inhibiting the production of interferon-alpha at a proximal step in the inflammatory cascade." Posada set up Resolve as a new kind of biotech which would partner with researchers on their drug prospects, giving the investigators a bigger share of the upside on successful programs. Release

> A new study has offered data to support the use of Sanofi's ($SNY) Sklice, which in tablet form was used to treat worms, against lice. Story

> In a new study a PCSK9 antibody from Sanofi and Regeneron combined with a high dose of atorvastatin easily beat out a solo high dose of atorvastatin in reducing high levels of LDL in patients with hypercholesterolemia . Patients who received SAR236553/REGN727 administered in a 1 ml injection every two weeks plus atorvastatin 80 mg achieved a mean reduction of 73% in LDL-C, compared to a mean reduction of 17% for patients who switched to atorvastatin 80 mg alone after 8 weeks. Release

Pharma News

@FiercePharma: Spectrum rejigs sales ops after Allos buyout, to tout its 3-drug stable. Prep for new ones, too. More | Follow @FiercePharma

> Pfizer discloses $491M charge for Rapamune marketing settlement. Story

> Watson CEO eyes cost cuts, brand growth as Actavis deal closes. Article

> Switzerland, Canada clear Novartis flu vaccines after tests. News

Medical Device News

 @FierceMedDev: Michael Mahoney, Boston Scientific's new CEO, inherits a giant in transition on day one. More | Follow @FierceMedDev

 @MarkHFierce: Advanced Cell Diagnostics pulled in $12 million in new Series B financing. More | Follow @MarkHFierce

 @DamianFierce: It's campaign season, and medical device companies are donating big. Find out how and to whom in our report. More | Follow @DamianFierce

> Medtronic closes $816M buyout of Chinese devicemaker. News

> BD completes $730M sale of labware unit. Item

> Disgraced former head of defunct French breast implant maker freed from jail. Article

Vaccines News

 @AlisonBFierce: In search of a lasting flu vaccine: Researchers work to find decades of protection with one shot. More | Follow @AlisonBFierce

> Health officials clash over whether to scrap malaria program. Item

> Mumps vaccine succumbs to face-to-face contact. Story

> U.K.'s HPA lands $6.4M for anthrax vaccine research. Article

> Study: Flu vaccine protects against heart attacks. More

Pharma Manufacturing News

> Lonza whacking 500 jobs, 400 at Swiss API plant. Story

> Compounder recall may make drug shortages more severe. News

> Novartis adding $500M biologics plant in Singapore. Report

> Boston-area pharma plant goes up for auction to pay debts. More

And Finally… A Johns Hopkins study suggests that schizophrenics are significantly more likely to live longer if they take their antipsychotic drugs on schedule, avoid extremely high doses and also regularly see a mental health professional. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.